Extended indication Treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Therapeutic value No estimate possible yet
Registration phase Positive CHMP opinion

Product

Active substance Coördinatiecomplex van ijzercitraat
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Metabolic diseases
Extended indication Treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Proprietary name Xoanacyl
Manufacturer Averoa
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date April 2024
Expected Registration June 2025
Orphan drug No
Registration phase Positive CHMP opinion
Additional remarks Positieve CHMP-opinie in maart 2025.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 3 times a day
Additional remarks Begindosis is 2 tabletten oraal 3 keer per dag bij de maaltijd. Pas de dosis zo nodig aan met 1 tot 2 tabletten om de serumfosfor op het gewenste niveau te houden, tot een maximum van 12 tabletten per dag. De dosis kan met tussenpozen van 1 week of langer worden getitreerd.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information